| Date | Time | Source | Headline | Symbol | Company |
| 11/29/2010 | 12:45PM | Business Wire | Impax Laboratories Confirms Patent Suit Relating to Generic Concerta® 54 mg Tablets | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/26/2010 | 9:00AM | Business Wire | Impax Laboratories to Present at the Piper Jaffray Annual Healthcare Conference | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/26/2010 | 8:30AM | Business Wire | Impax Laboratories Confirms Patent Challenge Relating to SIMCOR® Extended-Release Tablets, 1000/20 mg | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/22/2010 | 9:15AM | Business Wire | Impax Confirms Patent Challenge Relating to WELCHOL® for Oral Suspension, 3.75 gm/packet and 1.875 gm/packet | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/22/2010 | 9:00AM | Business Wire | Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta® Delayed-Release 20, 30 and 60 mg Capsules | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/18/2010 | 8:00AM | Business Wire | Impax Pharmaceuticals Announces IPX066 Demonstrates Efficacy & Safety in APEX-PD Phase III Study in Treatment of Early Parkin... | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/16/2010 | 9:15AM | Business Wire | Impax Laboratories Receives Final FDA Approval for Generic Allegra-D 60mg/120mg Tablets | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/09/2010 | 9:23AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/05/2010 | 10:00AM | Business Wire | Impax Laboratories to Present at the Credit Suisse 19th Annual Healthcare Conference | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/04/2010 | 4:50PM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/03/2010 | 10:24AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/02/2010 | 10:34AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/02/2010 | 7:00AM | Business Wire | Impax Laboratories Reports Growth in Revenue, Profit and Earnings in the Third Quarter 2010 | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/01/2010 | 10:32AM | Business Wire | Impax Laboratories Announces Litigation Against Shire Relating to Supply of Generic Adderall XR® | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 11/01/2010 | 8:40AM | Dow Jones News | Shire: Impax Laboratories Files For Intuniv Generic Drug Application | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 10/22/2010 | 12:10PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 10/04/2010 | 12:00PM | Business Wire | Impax Laboratories Schedules Conference Call and Webcast for Third Quarter 2010 Financial Results | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 10/01/2010 | 3:54PM | Dow Jones News | J&J Prepares For Generic Competition For ADHD Drug | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 09/30/2010 | 9:00AM | Business Wire | Impax Laboratories to Present at the Jefferies 2010 Global SpecPharma and European Healthcare Conference | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 09/15/2010 | 9:30AM | Business Wire | Impax Laboratories to Present at the UBS Global Life Sciences Conference | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 09/08/2010 | 10:00AM | Business Wire | Impax Laboratories to Present at the Morgan Stanley Global Healthcare Conference | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/25/2010 | 9:00AM | Business Wire | Impax Pharmaceuticals Completes Enrollment in ADVANCE-PD Phase III Trial of IPX066 in Parkinson’s Disease | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/20/2010 | 1:03PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/20/2010 | 9:00AM | Business Wire | Impax Laboratories Confirms Patent Challenge Relating to VYTORIN®, 10 mg/80 mg | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/17/2010 | 2:37PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/17/2010 | 2:31PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/12/2010 | 4:02PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/12/2010 | 3:03PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/12/2010 | 2:31PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 08/12/2010 | 2:29PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |